CAAS Capital Management’s BioNTech BNTX Stock Holding History

CAAS Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,500	Closed	-$522K	–	852
2022 Q2	$522K	Buy	+3,500	New	+$535K	0.03%	509
2022 Q1	–	Sell	-18,500	Closed	-$4.77M	–	682
2021 Q4	$4.77M	Hold	18,500	–	–	0.12%	189
2021 Q3	$5.05M	Hold	18,500	–	–	0.1%	198
2021 Q2	$4.14M	Sell	18,500 -1,500	-8%	-$283K	0.07%	275
2021 Q1	$2.18M	Buy	+20,000	New	+$2.12M	0.02%	575

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

CAAS Capital Management's BNTX Position: Q1 2025 in Review

CAAS Capital Management held its BioNTech (BNTX) position steady in Q1 2025 at 17,190 shares worth $1.57M. The position accounts for 0.17% of the portfolio, ranked #136.

CAAS Capital Management first reported a position in BNTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $2.04M in Q3 2024. 280 funds tracked by Wall St. Rank hold BNTX as of Q1 2025.

CAAS Capital Management held 17,190 shares of BioNTech worth $1.57M as of Q1 2025.
CAAS Capital Management left its BioNTech share count unchanged in Q1 2025.
BioNTech made up 0.17% of CAAS Capital Management's portfolio in Q1 2025, its #136 holding.
CAAS Capital Management first reported a position in BioNTech in Q1 2021 and has held it in 10 quarters since.
CAAS Capital Management's BioNTech position peaked at $2.04M in Q3 2024.
280 funds tracked by Wall St. Rank held BioNTech as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.